PMC full text:
Published online 2012 Mar 14. doi: 10.1371/journal.pone.0031334
Table 4
Secondary Performance Endpoint Improvements in Stage 1.
| Rintatolimod | Placebo | |||||
| Secondary Performance Endpoint | Baseline | Week 40 | p-value1 | Baseline | Week 40 | p-value1 |
| Karnofsky Performance Score (KPS) | 50 | 55 | <0.01 | 50 | 50 | <0.01 |
| Activities of Daily Living (ADL) | 68.1 | 72.4 | <0.01 | 68.7 | 69.4 | ns2 |
| Vitality Score (SF-36) | 5.0 | 10.0 | <0.01 | 10.0 | 10.0 | ns2 |
| General Health Perception (SF-36) | 20 | 20 | ns2 | 20 | 25 | <0.01 |
1p-value derived from a Wilcoxon signed rank test comparing whether the median change from Baseline is equal to 0 within each treatment group.
2ns = not significant, p>0.05.
